NEW YORK (GenomeWeb) – Admera Health today announced that its PGxOne Plus and OncoGxOne molecular diagnostic tests have been approved for clinical use by the New Jersey Department of Health.

PGxOne is a companion diagnostic test to help predict response to therapy based on the patients' genetics. The gene panel, which assays 25 genes known to determine drug response, is an expanded version of Admera's PGxOne test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.